Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Predicting higher risk factors for COVID-19 short-term reinfection in patients with rheumatic diseases: a modeling study based on XGBoost algorithm.
J Transl Med
December 2024
Department of Rheumatology and Immunology, Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Tianhe District, Guangzhou, China.
Background: Corona virus disease 2019 (COVID-19) reinfection, particularly short-term reinfection, poses challenges to the management of rheumatic diseases and may increase adverse clinical outcomes. This study aims to develop machine learning models to predict and identify the risk of short-term COVID-19 reinfection in patients with rheumatic diseases.
Methods: We developed four prediction models using explainable machine learning to assess the risk of short-term COVID-19 reinfection in 543 patients with rheumatic diseases.
Structured and prompt treatment of early arthritis in clinical practice leverages window of opportunity and leads to excellent clinical outcomes: an innovative retrospective cohort study.
Clin Rheumatol
December 2024
Rheumatology Department, Unidade Local de Saúde de Santa Maria, Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal.
Objectives: With this work, we evaluated the impact of the Lisbon Early ARthritis cliNic (LEARN) on untreated inflammatory arthritis clinical and patient-reported outcomes.
Methods: A retrospective cohort study enrolled patients in LEARN since its inception. Patients were followed for 12 months and treated to achieve disease remission.
Cancer-related fatigue and activities of daily living: lessons learned from the COVID-19 pandemic.
BMC Palliat Care
April 2024
Universidad Pontificia Comillas, Health Sciences Department, Madrid, Spain.
Background: Cancer-related fatigue is a prevalent condition in all stages of oncologic disease that is poorly diagnosed, with a negative impact on physical function to perform activities of daily living. Fatigue is also one of the main manifestations in post-COVID-19 syndrome, and few studies have explored the functionality of cancer patients after infection by the new coronavirus. This study was designed to assess cancer-related fatigue symptoms and their implications on physical function and quality of life during the pandemic.
View Article and Find Full Text PDF5-EPIFAT trial protocol: a multi-center, randomized, placebo-controlled trial of the efficacy of pharmacotherapy for fatigue using methylphenidate, bupropion, ginseng, and amantadine in advanced cancer patients on active treatment.
Trials
April 2024
Department of Health and Caring Sciences, Faculty of Health and Life Sciences, Linnaeus University, Kalmar/Växjö, Kalmar, Sweden.
Background: Cancer-related fatigue (CRF) is still undertreated in most patients, as evidence for pharmacological treatments is limited and conflicting. Also, the efficacy of the pharmacological agents relative to each other is still unclear. Therefore, medications that may potentially contribute to improving CRF will be investigated in this head-to-head trial.
View Article and Find Full Text PDFUnmet spiritual needs in palliative care: psychometrics of a screening checklist.
BMJ Support Palliat Care
October 2023
University of Notre Dame Australia, School of Medicine, Sydney, NSW, Australia.
Background: While studies in palliative care use measures of spirituality and religious belief, there have been few validation studies of a screening tool that identifies unmet spiritual needs.
Methods: A multidisciplinary research team developed and examined the usefulness, reliability and validity of a 17-item Spiritual Concerns Checklist (SCC) as a screening tool for unmet spiritual needs. A cohort of patients recruited from three palliative care services in Sydney and Melbourne, Australia completed anonymous questionnaires.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!